Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02865538 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT02865538 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 76 participants.
The verdict
NCT02865538, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts. Each cohort will comprise of 20 subjects. Subjects will be dosed for 14 days.
Interventions
- DRUG BAY3427080
- DRUG Placebo (for BAY3427080)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2017-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02865538
The ClinicalTrials.gov registry entry for NCT02865538 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BAY3427080 is the first listed.
NCT02865538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02865538 about?
NCT02865538 is a clinical study titled "Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms". This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts. Each cohort will comprise of 20 subjects. Subjects will be dosed for 14 days.
What is the current status of trial NCT02865538?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2016-08-01. Estimated completion is 2017-03-28.
What interventions are being tested in trial NCT02865538?
The interventions under investigation include: BAY3427080 (DRUG), Placebo (for BAY3427080) (DRUG).
Who is sponsoring clinical trial NCT02865538?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.